These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 31661064

  • 1. Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation
.
    Kim JS, Foster KW, Westphal SG.
    Clin Nephrol; 2020 Jan; 93(1):51-56. PubMed ID: 31661064
    [Abstract] [Full Text] [Related]

  • 2. C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.
    Garg N, Zhang Y, Nicholson-Weller A, Khankin EV, Borsa NG, Meyer NC, McDermott S, Stillman IE, Rennke HG, Smith RJ, Pavlakis M.
    Nephrol Dial Transplant; 2018 Dec 01; 33(12):2260-2265. PubMed ID: 29370420
    [Abstract] [Full Text] [Related]

  • 3. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM, Brophy PD.
    Curr Opin Pediatr; 2013 Apr 01; 25(2):225-31. PubMed ID: 23486421
    [Abstract] [Full Text] [Related]

  • 4. C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial.
    Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, Rubis N, Peraro F, Gaspari F, Pasini A, Rigotti A, Lerchner RM, Santoro D, Pisani A, Pasi A, Remuzzi G, EAGLE Study Group.
    Am J Kidney Dis; 2019 Aug 01; 74(2):224-238. PubMed ID: 30929851
    [Abstract] [Full Text] [Related]

  • 5. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy.
    Kersnik Levart T, Ferluga D, Vizjak A, Mraz J, Kojc N.
    Diagn Pathol; 2016 Oct 07; 11(1):94. PubMed ID: 27717365
    [Abstract] [Full Text] [Related]

  • 6. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
    Regunathan-Shenk R, Avasare RS, Ahn W, Canetta PA, Cohen DJ, Appel GB, Bomback AS.
    Am J Kidney Dis; 2019 Mar 07; 73(3):316-323. PubMed ID: 30413277
    [Abstract] [Full Text] [Related]

  • 7. A case of C3 glomerulonephritis successfully treated with eculizumab.
    Payette A, Patey N, Dragon-Durey MA, Frémeaux-Bacchi V, Le Deist F, Lapeyraque AL.
    Pediatr Nephrol; 2015 Jun 07; 30(6):1033-7. PubMed ID: 25796589
    [Abstract] [Full Text] [Related]

  • 8. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
    Kaartinen K, Martola L, Räisänen-Sokolowski A, Meri S.
    Clin Immunol; 2018 Feb 07; 187():104-106. PubMed ID: 29097196
    [Abstract] [Full Text] [Related]

  • 9. Treatment of C3 glomerulopathy with complement blockers.
    Vivarelli M, Emma F.
    Semin Thromb Hemost; 2014 Jun 07; 40(4):472-7. PubMed ID: 24799307
    [Abstract] [Full Text] [Related]

  • 10. Successful Treatment of Posttransplant Recurrent Complement C3 Glomerulopathy with Eculizumab.
    Sahin H, Gok Oguz E, Akoglu H, Atilgan G, Ulusal Okyay G, Karaveli Gursoy G, Kip Teymur T, Ertoy D, Canbakan B, Ayli MD.
    Iran J Kidney Dis; 2018 Oct 07; 12(5):315-318. PubMed ID: 30367025
    [Abstract] [Full Text] [Related]

  • 11. Treating C3 glomerulopathy with eculizumab.
    Welte T, Arnold F, Kappes J, Seidl M, Häffner K, Bergmann C, Walz G, Neumann-Haefelin E.
    BMC Nephrol; 2018 Jan 12; 19(1):7. PubMed ID: 29329521
    [Abstract] [Full Text] [Related]

  • 12. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature.
    Fernandez-Ruiz R, Blank RB, Wu M, Belmont HM.
    Lupus; 2021 Sep 12; 30(10):1671-1678. PubMed ID: 34192954
    [Abstract] [Full Text] [Related]

  • 13. Eculizumab and recurrent C3 glomerulonephritis.
    Gurkan S, Fyfe B, Weiss L, Xiao X, Zhang Y, Smith RJ.
    Pediatr Nephrol; 2013 Oct 12; 28(10):1975-81. PubMed ID: 23689905
    [Abstract] [Full Text] [Related]

  • 14. Recurrence and Outcomes of Complement-Related Renal Disease After Pediatric Renal Transplantation.
    Gulleroglu K, Baskin E, Ozdemir H, Moray G, Haberal M.
    Exp Clin Transplant; 2020 Jan 12; 18(Suppl 1):82-83. PubMed ID: 32008503
    [Abstract] [Full Text] [Related]

  • 15. C3 glomerulopathy and eculizumab: a report on four paediatric cases.
    Lebreton C, Bacchetta J, Dijoud F, Bessenay L, Fremeaux-Bacchi V, Sellier-Leclerc AL.
    Pediatr Nephrol; 2017 Jun 12; 32(6):1023-1028. PubMed ID: 28236143
    [Abstract] [Full Text] [Related]

  • 16. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M.
    Clin Exp Immunol; 2017 Feb 12; 187(2):304-315. PubMed ID: 27784126
    [Abstract] [Full Text] [Related]

  • 17. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.
    Am J Kidney Dis; 2017 Dec 12; 70(6):770-777. PubMed ID: 28821363
    [Abstract] [Full Text] [Related]

  • 18. Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft.
    Moog P, Jost PJ, Büttner-Herold M.
    BMC Nephrol; 2018 May 03; 19(1):106. PubMed ID: 29724174
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.